Biotechnology
XtalPi Debuts Kodexia™, the World's First Closed-Loop siRNA Platform Combining Generative AI with First-Principles Modeling
* This unified platform integrates sequence design, chemical modification, experimental validation, extrahepatic delivery design, and intellectual property strategy into an integrated computational–experimental workflow, pioneering in vivo efficacy prediction models to accelerate drug developme...
2026-10-06 22:42
2329
Hisun Pharmaceutical Celebrates 70th Anniversary with Global Partners at Milan-Taizhou Night
MILAN, Oct. 6, 2026 /PRNewswire/ -- Zhejiang Hisun Pharmaceutical Co., Ltd. hosted its 70th Anniversary Global Partners Appreciation Dinner in Milan on October 5, the eve of CPHI Milan 2026. Themed "Bridging Cultures, Advancing Health Together," the event brought together leading pharmaceutical c...
2026-10-06 21:32
1193
Werfen Launches QUANTA Link® 5.0: A Modern, Web-Based Platform for Autoimmune Laboratory Workflow Management
A flexible, browser-based solution, QUANTA Link 5.0 centralizes autoimmune testing workflows. It enhances usability, streamlines workflows, and supports confident decision-making in today's autoimmune laboratories. SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Werfen today announced the global launch ...
2026-10-06 20:00
2422
/C O R R E C T I O N -- Piramal Pharma Solutions/
In the news release, Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility, issued 06-Oct-2026 by Piramal Pharma Solutions over PR Newswire, we are advised by the company that changes have been made to the caption accompanying the first ima...
2026-10-06 16:59
1985
Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins
* Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026 * The trial provided initial safety and tolerability data for Lu AF28996, with most treatment-emergent adverse events reported as mild...
2026-10-06 14:35
2545
Dr. Oregonin Completes U.S. FDA Registration for OLTIS DENTAL-X, Unveiling Oral-Care Innovation Rooted in Trans-Pacific Alder Research
Botanical oral-care product bridges 1974 Oregon State University discovery of 'oregonin' with 27 years of natural-product research by South Korean scientists. SEOUL, South Korea, Oct. 6, 2026 /PRNewswire/ -- Dr. Oregonin Inc. today announced that it has completed U.S. Food and Drug Administration...
2026-10-06 13:50
1881
CHANDO Group Presents 20 Research Papers at IFSCC 2026 Congress in Perth
12 years of participation underscore the Group's growing presence in global cosmetics science SHANGHAI and PERTH, Australia, Oct. 6, 2026 /PRNewswire/ -- The 36th Congress of the International Federation of Societies of Cosmetic Chemists (IFSCC) was held in Perth, Australia, from September 28 to...
2026-10-06 11:40
1267
Fapon Showcases High-Performance IVD Raw Materials at JACLaS EXPO 2026
KOBE, Japan, Oct. 6, 2026 /PRNewswire/ -- Fapon, a trusted global IVD provider, will showcase its one-stop IVD solution at JACLaS EXPO 2026, held October 8–10 in Kobe, Japan. Visit Booth B32, Hall 1, 1st Floor. Fapon will spotlight its latest breakthroughs in small molecule sandwich antibodies a...
2026-10-06 08:00
1204
EpiSign and Geneyx Announce Partnership to Integrate Genomic and Epigenomic Analysis for Rare Disease
Collaboration brings EpiSign's comprehensive DNA methylation episignature analysis together with the Geneyx genomic and multi-omics analysis platform LONDON, ON and HERZLIYA, Israel, Oct. 5, 2026 /PRNewswire/ -- EpiSign Inc. and Geneyx Genomex Ltd. today announced a partnership to advance the in...
2026-10-05 21:52
3065
OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.
* OMLYCLO® (omalizumab-igec) is the first and onlyFDA-approved omalizumab biosimilar approved for all four indications of XOLAIR® (omalizumab) and designated as interchangeable with XOLAIR; OMLYCLO® will be available in 75 mg/0.5 mL, 150 mg/mL and 300mg/2mL in a single-dose prefilled syringe fo...
2026-10-05 20:45
2993
Ajinomoto Bio-Pharma Services Unveils Refreshed Global Brand, Showcasing its Strength in Specialization
* Reflects the depth of expertise and innovation Aji Bio-Pharma brings to customers navigating increasingly demanding development and manufacturing challenges TOKYO, Oct. 5, 2026 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a global network of specialized contract developme...
2026-10-05 19:00
3976
Energenesis Biomedical and Yoo Young Pharm Sign MOU for ENERGI-F703DFU Development and Commercialization in Korea
TAIPEI, Oct. 5, 2026 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657) today announced that it has signed a Memorandum of Understanding ("MOU") with Yoo Young Pharm. Co., Ltd. ("YYP"), a South Korea-based pharmaceutical company, to explore a collaboration for the development, registra...
2026-10-05 18:00
1993
EVIDENT Completes Acquisition of CrestOptics S.p.A.
NEEDHAM, Mass., Oct. 5, 2026 /PRNewswire/ -- Evident announced today that it has completed the acquisition of CrestOptics S.p.A., a Rome-based developer and manufacturer of advanced optical imaging systems for spinning disk confocal and super-resolution microscopy. The acquisition broadens Eviden...
2026-10-05 15:20
1700
Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers
Published multicenter study found higher complete wound closure rates and faster healing with Symphony plus standard of care AUCKLAND, New Zealand, Oct. 5, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today announced positive results from a prospec...
2026-10-05 12:46
2125
AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)
The only known investigational therapy for SBMA in Phase 3 development worldwide * AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBMA, or Kennedy's disease) * Following submission of the Ph...
2026-10-05 12:30
2353
Celaid Therapeutics Completes Second Close of Series B Financing Round
Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 TOKYO, Oct. 4, 2026 /PRNewswire/ -- Celaid Therapeutics Inc. (Head Office: Bunkyo-ku, Tokyo, Japan; President and CEO: Nobuyuki Arakawa; "Celaid") today announced the complet...
2026-10-05 09:30
1524
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 5, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global collab...
2026-10-05 05:46
3425
SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
MILAN, Oct. 4, 2026 /PRNewswire/ -- At the European Association for the Study of Diabetes (EASD) 2026, SiBionics presented "See More, Act Earlier," connecting continuous sensing with future diabetes care. Three exhibition chapters shaped this vision: "See More: Beyond Glucose," covering glucose, ...
2026-10-04 10:47
2241
Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy
* First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a monogenic disease. * Paired muscle biopsies reveal 3.5- to 5.3-fold increases in sarcolemmal utrophin expression,...
2026-10-03 19:30
5956
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026
SHANGHAI and HONG KONG, Oct. 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dise...
2026-10-03 08:30
10052
Week's Top Stories
Most Reposted
DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 276 media titles]
2026-10-06 05:28Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 271 media titles]
2026-10-01 10:00
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 269 media titles]
2026-09-30 10:50
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
Sunway University to Host Asia's First Global Tipping Points Conference 2026
[Picked up by 263 media titles]
2026-09-30 12:11
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
23821
